TLDRInsmed (INSM) stock jumped 16% in morning trading on a report that Sanofi is weighing a takeover.A volatility circuit breaker briefly paused trading in the stock.The stock hit $148.94 before easing back to about $139.18.Talks are ongoing, and any deal could still be weeks away.Insmed beat Q3 revenue estimates and raised its outlook for BRINSUPRI and ARIKAYCE.Insmed (INSM) stock spiked 16% in morning trading on Thursday. The move came after word that Sanofi is weighing a takeover.Insmed Incorporated, INSMThe surge was fast enough to trip a volatility circuit breaker. Trading in the stock paused for a short time.The stock touched an intraday high of $148.94. It then cooled to around $139.18.Sanofi is weighing an acquisition of US drugmaker Insmed, people familiar with the matter said, in what would be the largest biopharma deals in years https://t.co/cB0wJDnnDY— Bloomberg (@business) November 19, 2026Bloomberg reported that Sanofi is speaking with advisers about a possible deal. The report cited people familiar with the matter who asked not to be named.A Deal Still Far From CertainDeliberations are described as ongoing, with no guarantee of an agreement. Other potential buyers could also appear.That uncertainty helps explain the fade from the high. Traders were pricing a maybe, not a done deal.Sanofi said it does not comment on market rumors. Insmed did not immediately respond to requests for comment.LSEG data puts Insmed’s market value at $26.28 billion. A completed deal would rank among the largest biopharma acquisitions in recent times.The Business Behind the BuzzThe buzz landed on a company with a solid recent record. Insmed’s third-quarter 2026 revenue beat analyst estimates.Management also raised its full-year outlook for BRINSUPRI and ARIKAYCE. Both products are central to the company’s growth story.Wall Street was already leaning positive. Goldman Sachs, HC Wainwright and Guggenheim carry Buy-equivalent ratings.Their price targets sit well above where the stock traded before the news. So the report arrived with analyst support already in place.Quotes during the session ranged from roughly 14% to 21% higher, depending on when traders checked. Sanofi’s own stock rose about 1.5% to 85.07 euros in Paris.Deliberations are ongoing, and any deal could still be weeks away.The post Insmed (INSM) Stock Jumps 16% as Sanofi Takeover Talks Trigger Trading Halt appeared first on Blockonomi.